| Status | 進行中Working |
| Amantadine for Antipsychotic-associated Weight Gain: Meta-analysis of Randomized Placebo-Controlled Trials. | |
Zheng , W; GS, U; CM, N; Yang , X; Gu , Y.; Li , M; Xiang , Y.; Xiang, Y.
| |
| Source Publication | Journal of Clinical Psychopharmacology.
 |
| ISSN | 1533-712X |
| Abstract | Weight gain associated with antipsychotics (AP) in schizophrenia has been an ongoing concern. This meta-analysis examined the efficacy and safety of amantadine as an adjunctive treatment for weight gain in schizophrenia by systematically searching and analyzing randomized controlled trials (RCTs). RCTs comparing adjunctive amantadine with placebo in adult patients with schizophrenia were included in the meta-analysis. Two independent investigators searched the literature and extracted data. Weighted and standardized mean differences (WMDs/SMDs) and risk ratio (RR) ±95% confidence intervals (CIs) were calculated. Five RCTs (n=265) with double-blinded design lasting 8.2±5.9 weeks, were included in the analysis. Amantadine outperformed placebo regarding weight reduction with moderate effect size (trials=3, n=205, WMD: –2.22kg, P=0.001; I2=45%). Amantadine also outperformed placebo at endpoint in the negative [the Positive and Negative Syndrome Scale (PANSS) (1 trial) and the Scale for the Assessment of Negative Symptoms (SANS) (1 trial)] symptom scores (trials=2, n=84, SMD: -0.56, P=0.01; I2=12%), but not in the PANSS total scores (trials=2) (SMD: -0.31, P=0.16; I2=0%) and the positive [(PANSS) (1 trial) and the Scale for the Assessment of Positive Symptoms (SAPS) (1 trial)] symptom scores (SMD: 0.13, P=0.54; I2=0%). Except for insomnia, (p=0.007, NNH=6, 95% CI=4-16), all-cause discontinuation (RR: 1.12, p=0.54, I2=0%) and other adverse events were similar between the amantadine and placebo groups. According to this meta-analysis of 5 RCTs adjunctive amantadine appears to be an effective option for attenuating AP-related weight gain in patients with schizophrenia. More RCTs are needed to inform clinical recommendations. |
| Keyword | amantadine schizophrenia weight gain meta-analysis |
| Language | 英語English |
| The Source to Article | PB_Publication |
| PUB ID | 26603 |
| Document Type | Journal article |
| Collection | DEPARTMENT OF PUBLIC HEALTH AND MEDICINAL ADMINISTRATION |
| Corresponding Author | Xiang, Y. |
| Recommended Citation GB/T 7714 | Zheng , W,GS, U,CM, N,et al. Amantadine for Antipsychotic-associated Weight Gain: Meta-analysis of Randomized Placebo-Controlled Trials.[J]. Journal of Clinical Psychopharmacology.. |
| APA | Zheng , W., GS, U., CM, N., Yang , X., Gu , Y.., Li , M., Xiang , Y.., & Xiang, Y. Amantadine for Antipsychotic-associated Weight Gain: Meta-analysis of Randomized Placebo-Controlled Trials.. Journal of Clinical Psychopharmacology.. |
| MLA | Zheng , W,et al."Amantadine for Antipsychotic-associated Weight Gain: Meta-analysis of Randomized Placebo-Controlled Trials.".Journal of Clinical Psychopharmacology. . |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment